or Try an Advanced Search...

    Ocular Hypertension Stocks List

    Symbol Grade Name % Change
    ABBV D AbbVie Inc. 3.04
    BLCO D Bausch + Lomb Corporation -1.21
    OCUL D Ocular Therapeutix, Inc. 3.64
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Major Medical Instruments & Supplies
    Related Stock Lists: Cataract Surgery Cataracts Glaucoma Treatment Of Glaucoma Adalimumab Advanced Prostate Cancer Allergic Conjunctivitis Allergology Anemia Atopic Dermatitis Autoimmune Disease Blood Cancers Chronic Idiopathic Constipation Clinical Trial Combination Drugs Conjunctivitis Constipation Contact Lenses Cornea Crohn's Disease

    Related ETFs - A few ETFs which own one or more of the above listed Ocular Hypertension stocks.

    Symbol Grade Name Weight
    HDLB B ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B due September 30, 2044 9.8
    BOTZ B Global X Robotics & Artificial Intelligence Thematic ETF 9.31
    MEDX F Horizon Kinetics Medical ETF 7.81
    GRID C First Trust NASDAQ Clean Edge Smart Grid Infrastructure Index Fund 7.75
    FDL A First Trust Morningstar ETF 6.79
    View all Ocular Hypertension ETFs...
    Compare ETFs
    Compare HDLB to GRID Compare MEDX to FDL Compare MEDX to GRID

        Ocular Hypertension Stocks Recent News

        Date Stock Title
        Nov 22 ABBV AbbVie gains on Leerink Partners upgrade to Outperform
        Nov 22 ABBV AbbVie: Upgrading To 'Strong Buy' After Pullback
        Nov 22 BLCO Bausch & Lomb Corporation (BLCO)-A Bull Case Theory
        Nov 22 ABBV J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
        Nov 22 ABBV AbbVie Jumps Nearly 4% On An Upgrade Despite Bristol Myers-Tied Setback
        Nov 22 ABBV AbbVie upgraded to outperform by Leerink on recent sell-off
        Nov 20 ABBV Unpacking the Latest Options Trading Trends in AbbVie
        Nov 19 ABBV Where Will AbbVie Be in 5 Years?
        Nov 19 ABBV ALDX Up as FDA Accepts Resubmitted NDA for Eye Drug Reproxalap
        Nov 19 ABBV RVPH: Year-End OLE Update
        Nov 19 ABBV What is a ‘cure,’ really? AbbVie’s Humira creator leaps into the next phase of medicine
        Nov 18 ABBV AbbVie snaps eight straight sessions of losses
        Nov 18 ABBV Aldeyra announces FDA acceptance of resubmitted reproxalap application
        Nov 18 ABBV AbbVie's Ovarian Cancer Drug Elahere Gets Approval in Europe
        Nov 18 ABBV Allergan Aesthetics Offers Free Business Education Courses Online to Support Growing Practices with Allergan Aesthetics Products
        Nov 18 ABBV AbbVie’s Elahere wins European approval for certain ovarian cancers
        Nov 18 ABBV Why This Beaten-Down Dividend Stock Is a No-Brainer Buy on the Dip
        Nov 18 ABBV AbbVie Receives European Commission Approval of ELAHERE® (mirvetuximab soravtansine) for the Treatment of Platinum-Resistant Ovarian Cancer
        Nov 17 ABBV Super Micro Computer, Moderna And XPeng Were Among Top 10 Large Cap Stocks Losing Big Last Week (November 11-15): Check Out Other Losers
        Nov 17 ABBV AbbVie's (NYSE:ABBV) Shareholders Will Receive A Bigger Dividend Than Last Year
        Related Industries: Biotechnology Drug Manufacturers - Major Medical Instruments & Supplies
        Related Stock Lists: Cataract Surgery Cataracts Glaucoma Treatment Of Glaucoma Adalimumab Advanced Prostate Cancer Allergic Conjunctivitis Allergology Anemia Atopic Dermatitis Autoimmune Disease Blood Cancers Chronic Idiopathic Constipation Clinical Trial Combination Drugs Conjunctivitis Constipation Contact Lenses Cornea Crohn's Disease
        Ocular Hypertension

        Browse All Tags